Published on 28/11/2025

Biologics & ATMPs: CPV Considerations

Understanding Continued Process Verification in Biologics and ATMPs

Continued Process Verification (CPV) is a crucial component in the lifecycle management of Biologics and Advanced Therapy Medicinal Products (ATMPs). It signifies an evolution from traditional quality assurance approaches to a more continuous and proactive methodology. Under the FDA, EU GMP Annex 15, and other regulatory frameworks, the focus is on real-time monitoring and evaluation during the production and post-launch phases of biologics and ATMPs.

The goal of CPV is to ensure consistent production that complies with defined specifications and standards, leading to effective risk management and mitigation strategies compliant with ICH Q9 risk management.

In this guide, we will cover essential steps for establishing an effective CPV program for biologics and ATMPs, with particular emphasis on the development of a robust sampling plan, acceptance criteria, and regulatory considerations.

Step 1: Establishing a CPV Framework

To initiate a CPV strategy, a clear framework integrating quality design, process understanding, and risk management is imperative. This framework forms the basis for monitoring and understanding critical process parameters and quality attributes.

• Define Objectives: Determine the objectives of the CPV framework aligned with regulatory expectations and organizational goals.
• Identify Key Quality Attributes (KQAs): Identify KQAs that impact product quality and patient safety through risk assessment methodologies.
• Characterize Critical Process Parameters (CPPs): Define CPPs that directly influence the KQAs to ensure effective monitoring and control throughout the manufacturing process.

Documentation supporting this framework should be created which will aid in regulatory submissions and inspections by demonstrating a thorough understanding of the process as stipulated in FDA Process Validation guidance and Annex 15 Validation.

Step 2: Developing a Continued Process Verification Sampling Plan

Integrating a comprehensive PPQ sampling plan is vital for the successful execution of CPV. The plan should incorporate statistical sampling methods to ensure that the data collected are representative of the manufacturing process.

The following elements should be considered in developing a robust sampling plan:

• Sampling Frequency: Establish the frequency of sampling based on risk assessment; higher risks may require more frequent sampling.
• Sample Size: Determine an adequate sample size to yield statistically meaningful results. Consideration of variability and expected levels of control is necessary.
• Sample Representation: Ensure representativeness of samples across all shifts, batches, and operators to detect any variations.

Documentation of the sampling plan should define the sampling rationale clearly, mitigating any uncertainty during regulatory audits and inspections.

Step 3: Data Collection and Monitoring

Once the sampling plan is in place, systematic data collection and monitoring is essential to enhance process understanding. Data should be gathered from multiple sources within the manufacturing environment to provide a holistic view of the process.

• Automated Data Collection: Implement automated systems for real-time data acquisition whenever possible. This would enhance the reliability of the data and facilitate compliance with 21 CFR Part 11 for electronic records and signatures.
• Process Analytical Technology (PAT): Utilize PAT tools for continuous monitoring of critical parameters, ensuring they remain within defined limits.
• Statistical Process Control (SPC): Employ SPC tools to evaluate trends and variances in real-time data, aiding in the predictive management of quality attributes.

Document every data collection activity meticulously, as this serves as evidence for compliance to regulatory standards during evaluations by authorities such as the EMA and the MHRA.

Step 4: Data Analysis and Interpretation

After data collection, the next phase involves thorough analysis to identify trends, variations, and areas requiring improvement. The analysis should include the following aspects:

• Trend Analysis: Identify significant trends over time to ascertain the process’s capability and performance against established benchmarks.
• Root Cause Analysis: Employ root cause analysis methodologies to identify sources of variability, integrating tools like fishbone diagrams and the 5 Whys technique.
• Performance Metrics: Develop key performance indicators (KPIs) to routinely evaluate the overall performance of the process.

Documentation should consist of comprehensive reports summarizing findings, highlighting process improvements, deviations, and corrective actions taken. This is essential for maintaining readiness for inspections by both national and international regulatory bodies.

Step 5: Implementation of Corrective and Preventive Actions (CAPA)

The essence of CPV lies in the ability to rapidly respond to identified issues. Corrective and Preventive Actions (CAPA) should be woven into the CPV program to ensure continuous improvement. Critical components include:

• Documented Procedures: Establish clear procedures defining how CAPA processes will be activated in response to any deviations detected during CPV.
• Training and Awareness: Continuous training programs should ensure that staff are familiar with CAPA processes and understand the importance of timely action.
• Monitoring Effectiveness: Track the implementation and effectiveness of CAPA initiatives through regular reviews and performance evaluations.

The effectiveness of CAPA initiatives must be documented to provide a traceable account of continuous improvement, further complying with regulatory guidelines and supporting future submissions.

Step 6: Regulatory Compliance and Reporting

Adherence to regulatory expectations during the CPV process is critical for securing and maintaining product approvals. The following elements contribute to regulatory compliance:

• Periodic Review: Conduct regular reviews of the CPV plan and its outcomes to ensure it remains aligned with the evolving regulatory standards as indicated in EU GMP Annex 15.
• Communication with Regulatory Authorities: Maintain transparency with regulatory authorities regarding CPV activities, reporting any significant deviations and corrective measures in a timely fashion.
• Documentation of Compliance: Compile and maintain comprehensive documentation to serve as evidence during inspections and audits.

This rigorous practice not only establishes compliance with regulatory requirements but also reinforces stakeholder confidence in the product’s quality and safety profile.

Step 7: Continuous Improvement and Adaptation

The completion of CPV does not mark the endpoint but initiates a cycle of continuous improvement. A robust feedback loop should be implemented to incorporate learnings into future product lifecycle activities. Consider the following:

• Regular Training Updates: Continuously update training programs to reflect technological advancements and regulatory changes that impact CPV.
• Leveraging Technology: Invest in advanced analytics tools and artificial intelligence platforms that can simplify data analysis and enhance predictive capabilities.
• Industry Benchmarking: Continuously benchmark processes against industry standards to identify areas for improvement.

Documentation of improvement activities and measurable outcomes becomes essential for refining processes and ensuring sustained compliance with both current and future regulatory expectations.

Conclusion

In conclusion, establishing a robust Continued Process Verification framework for Biologics and ATMPs is paramount in achieving consistent product quality and regulatory compliance. Following this step-by-step approach provides clarity in developing a CPV program while reinforcing an organization’s commitment to quality assurance.

By systematically defining objectives, developing a comprehensive sampling plan, and rigorously analyzing and adapting processes, manufacturers can navigate the complex landscape of regulatory requirements effectively. Consequently, this promotes not only patient safety but also product efficacy in the global market.